

About the “New Horizons for the Treatment of Non-small Cell Lung Cancer” Panel Participants:

Raghuram “Ram” Selvaraju, Ph.D.

Raghuram Selvaraju, Ph.D. is a Managing Director of Equity Research at H.C. Wainwright whose research focuses on the healthcare sector. He has over 15 years of experience on Wall Street and previously was a pharmaceutical researcher at Serono in Switzerland. In addition, Ram has appeared numerous times on Bloomberg, CNBC, Business News Network and BTV where he discussed drug development trends, healthcare reform policy, and pharma and biotech M&A. Prior to joining H.C. Wainwright, he held Senior Research positions at MLV & Co., Aegis Capital, Hapoolim Securities U.S.A. and Rodman & Renshaw LLC. He became the youngest-ever recipient of the Serono Pharmaceutical Research Institute’s Inventorship Award for exceptional innovation and creativity in 2003.

Dr. Selvaraju earned his Ph.D. in cellular immunology and molecular neuroscience and an M.S. in molecular biology from the University of Geneva in Switzerland on the basis of his drug development research. He holds an M.B.A. from the Cornell University accelerated one-year program for scientists and engineers. He holds a B.S. in biological sciences and technical writing from Carnegie Mellon University.

Yi-long Wu, M.D., Ph.D.

Prof. Yi-Long Wu is a tenured professor of Guangdong General Hospital, Guangdong Academy of Medical Sciences and Guangdong Lung Cancer Institute. He is Director of the National Lung Cancer Quality Control Center, former President of the Chinese Society of Clinical Oncology (CSCO), Chief of the WU JIEPING Oncology Medical Foundation, vice-director of the Precision Medicine of the Chinese Medical Doctor Association, President of the Chinese Thoracic Oncology Group(C-TONG), President of the International Chinese Society of Thoracic Surgery(ICSTS), Fellow of the American College of Surgeons, Board Member of Directors of the International Association Study of Lung Cancer(IASLC), Chairman of the European Society for Medical Oncology (ESMO) in China, Chairman of the Federation of Asia Clinical Oncology (FACO), former Member of the International Affairs Committee of American Society of Clinical Oncology (ASCO), and former Member of staging committee of the IASLC.

He graduated from Sun Yat-sen University of Medical Sciences in 1982, and completed his thoracic surgery training in Germany in 1989. His main research interests are the multidisciplinary synthetic therapy on lung cancer in translation medicine and evidence-based medicine in oncology. He is leading the Chinese lung cancer research field and has been the Principal Investigator or Co-PI of more than 90 international or national multicenter clinical trials. He has contributed 20 books on cancer and has published more than 300 articles in peer-reviewed journals, including J Clin Oncol, Lancet Oncol, New Engl J Med Cancer Cell, and J Thorac Oncol. He also serves on the editorial boards of Cancer Letters, Annals of Surgical Oncology, Lung Cancer Management, International Journal of Biological Marker, and General Thoracic and Cardiovascular Surgery. He is Editor-in-Chief of the Journal of Evidence-based Medicine, Journal of Thoracic Oncology (Chinese Edition), The Oncologist (Chinese Edition), etc.

Brian S. Henick, M.D.

Dr. Brian Henick is a medical oncologist at Columbia University Herbert Irving Comprehensive Cancer Center in New York City, where he focuses on improving treatment strategies for thoracic malignancies.

Dr. Henick believes in a multidisciplinary approach to treatment that includes the computational study of cancer immunobiology and the latest advancement in cancer care. With every patient he serves, his goal is improving the current treatment strategy by maximizing the vast resources of one of the country's leading cancer centers and its mesothelioma doctors.

Dr. Henick earned his M.D. at Rutgers New Jersey Medical School and conducted his Fellowship, Residency and Internship at Yale New Haven Hospital.

He is the recipient of numerous awards and recognitions including ASCO Journals Editorial Fellowship, the Conquer Cancer/ASCO Foundation Merit Award, the Conquer Cancer/ASCO Young Investigator Award, and the Society for Immunotherapy of Cancer Sparkathon. In addition, he was inducted into the Gold Humanism Honor Society.

Mike A. Royal, M.D.

Dr. Royal, Chief Medical Officer at Sorrento Therapeutics, is a pharmaceutical executive with 20 years of clinical development and medical affairs. Recently, he was the Chief Medical Officer of Suzhou Connect Biopharmaceuticals and, prior to that, Concentric Analgesics. He rejoins Sorrento where he was previously EVP, Clinical Development and Regulatory Affairs in 2016. He has been responsible for or instrumental in several successful NDAs, including NCEs, 505(b)(2)s and ANDAs.

Dr. Royal is board certified in internal medicine, pain medicine, anesthesiology with additional qualifications in pain management, addiction medicine and legal medicine. He has been an Assistant Professor of Medicine at the Uniformed Services University of Health Sciences, Assistant Professor of Anesthesiology/Critical Care Medicine at the University of Pittsburgh Medical Center, and an Adjunct Professor at University of Oklahoma and University of California San Diego.

Dr. Royal holds an M.D. from UMass Chan School of Medicine, an M.B.A. from New York University's Stern School of Business, a J.D. from University of Maryland Francis King Carey School of Law and a B.S. in Synthetic Organic Chemistry from Massachusetts Institute of Technology.

He has published extensively with over 190 book chapters, peer reviewed articles and abstracts/posters; and has been an invited speaker at national and international meetings.